top of page
NOBROLA
A TWO-STAGE SIMON DESIGN PHASE II STUDY OF SINGLE AGENT OLAPARIB FOR NON-BRCA METASTATIC BREAST CANCER PATIENTS WITH HRD
CLINICAL TRIAL DETAILS
TO EVALUATE OLAPARIB IN ADVANCED TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) AND NO GERMLINE BRCA1/2 MUTATIONS (gBRCA1/2mut).
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
Triple-Negative Breast Cancer
17
114 (6 eligible/treated)
IIa
Spain
Completed
TRIAL OVERVIEW
PRESS RELEASE
----
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
TRIAL SITES
----
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
TRIAL RESUME
bottom of page